TW202016306A - 用於基因編輯之經修飾引導rna - Google Patents
用於基因編輯之經修飾引導rna Download PDFInfo
- Publication number
- TW202016306A TW202016306A TW108120005A TW108120005A TW202016306A TW 202016306 A TW202016306 A TW 202016306A TW 108120005 A TW108120005 A TW 108120005A TW 108120005 A TW108120005 A TW 108120005A TW 202016306 A TW202016306 A TW 202016306A
- Authority
- TW
- Taiwan
- Prior art keywords
- modification
- nucleotides
- grna
- nucleotide
- modified
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 11
- 238000010362 genome editing Methods 0.000 title abstract description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title 1
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 1107
- 230000000694 effects Effects 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000012986 modification Methods 0.000 claims description 1781
- 230000004048 modification Effects 0.000 claims description 1780
- 125000003729 nucleotide group Chemical group 0.000 claims description 1777
- 239000002773 nucleotide Substances 0.000 claims description 1500
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 561
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 337
- 230000002441 reversible effect Effects 0.000 claims description 66
- 229930010555 Inosine Natural products 0.000 claims description 40
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 40
- 229960003786 inosine Drugs 0.000 claims description 40
- 102100039856 Histone H1.1 Human genes 0.000 claims description 38
- 101001035402 Homo sapiens Histone H1.1 Proteins 0.000 claims description 38
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 30
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 27
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 27
- 208000035657 Abasia Diseases 0.000 claims description 23
- 108091033409 CRISPR Proteins 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- 101710163270 Nuclease Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 239000011737 fluorine Substances 0.000 claims description 15
- 102100022653 Histone H1.5 Human genes 0.000 claims description 14
- 101000899879 Homo sapiens Histone H1.5 Proteins 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 229930024421 Adenine Natural products 0.000 claims description 12
- 229960000643 adenine Drugs 0.000 claims description 12
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 12
- 230000003370 grooming effect Effects 0.000 claims description 12
- 239000002777 nucleoside Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- -1 Bicyclic ribose analogs Chemical class 0.000 claims description 9
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 8
- 229930182480 glucuronide Natural products 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 150000008134 glucuronides Chemical class 0.000 claims description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 7
- 150000003230 pyrimidines Chemical class 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 102100023917 Histone H1.10 Human genes 0.000 claims description 6
- 102100039855 Histone H1.2 Human genes 0.000 claims description 6
- 102100027368 Histone H1.3 Human genes 0.000 claims description 6
- 102100027369 Histone H1.4 Human genes 0.000 claims description 6
- 102100033558 Histone H1.8 Human genes 0.000 claims description 6
- 102100023920 Histone H1t Human genes 0.000 claims description 6
- 101000905024 Homo sapiens Histone H1.10 Proteins 0.000 claims description 6
- 101001035375 Homo sapiens Histone H1.2 Proteins 0.000 claims description 6
- 101001009450 Homo sapiens Histone H1.3 Proteins 0.000 claims description 6
- 101001009443 Homo sapiens Histone H1.4 Proteins 0.000 claims description 6
- 101000872218 Homo sapiens Histone H1.8 Proteins 0.000 claims description 6
- 101000905044 Homo sapiens Histone H1t Proteins 0.000 claims description 6
- 101000897979 Homo sapiens Putative spermatid-specific linker histone H1-like protein Proteins 0.000 claims description 6
- 101000843236 Homo sapiens Testis-specific H1 histone Proteins 0.000 claims description 6
- 102100021861 Putative spermatid-specific linker histone H1-like protein Human genes 0.000 claims description 6
- 102100031010 Testis-specific H1 histone Human genes 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 125000003835 nucleoside group Chemical group 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 4
- 229930185560 Pseudouridine Natural products 0.000 claims description 4
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- 230000037429 base substitution Effects 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 4
- 150000002338 glycosides Chemical class 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 4
- 238000011191 terminal modification Methods 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940029575 guanosine Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 101100166144 Staphylococcus aureus cas9 gene Proteins 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000005782 double-strand break Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108091079001 CRISPR RNA Proteins 0.000 description 12
- 108091028113 Trans-activating crRNA Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 5
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 210000002925 A-like Anatomy 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682838P | 2018-06-08 | 2018-06-08 | |
| US201862682820P | 2018-06-08 | 2018-06-08 | |
| US62/682,820 | 2018-06-08 | ||
| US62/682,838 | 2018-06-08 | ||
| PCT/US2019/036160 WO2019237069A1 (en) | 2018-06-08 | 2019-06-07 | Modified guide rnas for gene editing |
| WOPCT/US19/36160 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202016306A true TW202016306A (zh) | 2020-05-01 |
Family
ID=68770688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108120005A TW202016306A (zh) | 2018-06-08 | 2019-06-10 | 用於基因編輯之經修飾引導rna |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210087568A1 (https=) |
| EP (1) | EP3802828A4 (https=) |
| JP (2) | JP7832761B2 (https=) |
| KR (2) | KR102919364B1 (https=) |
| CN (1) | CN112567036A (https=) |
| AU (2) | AU2019282824C1 (https=) |
| BR (1) | BR112020024731A2 (https=) |
| CA (1) | CA3102950A1 (https=) |
| CO (1) | CO2021000051A2 (https=) |
| IL (2) | IL278822B1 (https=) |
| MX (2) | MX2020013293A (https=) |
| PH (1) | PH12020552100A1 (https=) |
| SA (1) | SA520420729B1 (https=) |
| SG (1) | SG11202011539VA (https=) |
| TW (1) | TW202016306A (https=) |
| WO (1) | WO2019237069A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL314915B1 (en) | 2017-01-23 | 2026-02-01 | Regeneron Pharma | Variants of 17-beta-hydroxysteroid dehydrogenase and their uses |
| KR20190139869A (ko) | 2017-04-11 | 2019-12-18 | 리제너론 파마슈티칼스 인코포레이티드 | 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정 |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| WO2019028032A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF |
| CN111182790A (zh) | 2017-07-31 | 2020-05-19 | 瑞泽恩制药公司 | Crispr报告体非人类动物及其用途 |
| MX394999B (es) | 2017-09-29 | 2025-03-24 | Regeneron Pharma | Animales no humanos que comprenden un locus ttr humanizado y metodos de uso |
| US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| CN111885915B (zh) | 2018-03-19 | 2023-04-28 | 瑞泽恩制药公司 | 使用crispr/cas系统对动物进行转录调制 |
| JP7507093B2 (ja) | 2018-03-21 | 2024-06-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法 |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| JP7578590B2 (ja) | 2018-10-18 | 2024-11-06 | インテリア セラピューティクス，インコーポレーテッド | 第ｉｘ因子を発現するための組成物及び方法 |
| EP3946598A1 (en) * | 2019-03-28 | 2022-02-09 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| US11845957B2 (en) | 2019-06-14 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Models of tauopathy |
| WO2021026318A2 (en) * | 2019-08-06 | 2021-02-11 | The Penn State Research Foundation | Engineered crispr/cas9 systems for simultaneous long-term regulation of multiple targets |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| EP4438729A3 (en) * | 2019-12-09 | 2025-03-26 | Caribou Biosciences, Inc. | Crispr abasic restricted nucleotides and crispr accuracy via analogs |
| MX2022006950A (es) * | 2019-12-11 | 2022-11-07 | Intellia Therapeutics Inc | Arn guía modificados para edición de genes. |
| JP2023512758A (ja) | 2020-02-07 | 2023-03-29 | インテリア セラピューティクス，インコーポレイテッド | カリクレイン（ｋｌｋｂ１）遺伝子編集のための組成物および方法 |
| GB2632565B (en) * | 2020-04-09 | 2025-06-04 | Verve Therapeutics Inc | Base editing of PCSK9 and methods of using same for treatment of disease |
| WO2021231606A2 (en) * | 2020-05-12 | 2021-11-18 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| CA3204997A1 (en) | 2020-12-11 | 2022-06-16 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class ii in a cell |
| CR20230305A (es) | 2020-12-11 | 2023-11-10 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación |
| AU2021409732A1 (en) | 2020-12-23 | 2023-07-20 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
| TW202242101A (zh) | 2020-12-23 | 2022-11-01 | 美商英特利亞醫療公司 | 用於細胞中基因修飾ciita之組合物及方法 |
| JP2024505672A (ja) | 2021-02-08 | 2024-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法 |
| JP2024506016A (ja) | 2021-02-08 | 2024-02-08 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法 |
| WO2022170194A2 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
| EP4298212A4 (en) * | 2021-02-25 | 2026-04-15 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| EP4392060A1 (en) | 2021-08-24 | 2024-07-03 | Intellia Therapeutics, Inc. | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
| EP4426338A2 (en) | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| WO2023081687A1 (en) * | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| CN118632622A (zh) | 2021-12-08 | 2024-09-10 | 瑞泽恩制药公司 | 突变型肌纤蛋白疾病模型及其用途 |
| WO2023185697A2 (en) * | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
| CN114574598B (zh) * | 2022-04-02 | 2023-08-08 | 中国农业科学院北京畜牧兽医研究所 | 鉴定或辅助鉴定猪5/6肋眼肌面积的方法 |
| CN119923466A (zh) * | 2022-06-15 | 2025-05-02 | 比姆医疗股份有限公司 | 用于减少补体激活的组合物和方法 |
| CN119384498A (zh) | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| EP4540389A2 (en) | 2022-06-16 | 2025-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
| CN119585419A (zh) | 2022-06-29 | 2025-03-07 | 因特利亚治疗公司 | 工程化t细胞 |
| TW202417017A (zh) * | 2022-06-30 | 2024-05-01 | 香港商正基基因科技有限公司 | 具有化學修飾的導引rna |
| WO2024137766A2 (en) | 2022-12-21 | 2024-06-27 | Intellia Therapeutics, Inc. | Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing |
| WO2024138115A1 (en) | 2022-12-23 | 2024-06-27 | Intellia Theraperutics, Inc. | Systems and methods for genomic editing |
| WO2024186890A1 (en) | 2023-03-06 | 2024-09-12 | Intellia Therapeutics, Inc. | Compositions and methods for hepatitis b virus (hbv) genome editing |
| EP4677067A1 (en) | 2023-03-07 | 2026-01-14 | Intellia Therapeutics, Inc. | Cish compositions and methods for immunotherapy |
| IL324634A (en) | 2023-05-15 | 2026-01-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025007951A1 (zh) * | 2023-07-06 | 2025-01-09 | 上海交通大学 | 一种靶向ttr的sacas9 sgrna及其修饰方式 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| TW202521564A (zh) | 2023-08-14 | 2025-06-01 | 美商英特利亞醫療公司 | 用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法 |
| WO2025059328A1 (en) * | 2023-09-14 | 2025-03-20 | Empirico Inc. | Modified oligonucleotides |
| TW202540417A (zh) | 2023-11-10 | 2025-10-16 | 美商英特利亞醫療公司 | 用於基因體編輯之組合物、方法及系統 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137439A2 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025184520A1 (en) | 2024-02-29 | 2025-09-04 | Intellia Therapeutics, Inc. | Compositions and methods for angiopoietin like 3 (angptl3) editing |
| CN117925623B (zh) * | 2024-03-20 | 2024-06-07 | 北京引正基因科技有限公司 | 用于hao1基因编辑和治疗ph1的组合物 |
| WO2025240946A1 (en) | 2024-05-17 | 2025-11-20 | Intellia Therapeutics, Inc. | Lipid nanoparticles and lipid nanoparticle compositions |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150376586A1 (en) * | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| US10513711B2 (en) | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
| US10900034B2 (en) * | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| CN112877327B (zh) * | 2014-12-18 | 2024-11-22 | 综合基因技术公司 | 基于crispr的组合物和使用方法 |
| EP3280803B1 (en) * | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| US11279928B2 (en) * | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| EP3159407A1 (en) * | 2015-10-23 | 2017-04-26 | Silence Therapeutics (London) Ltd | Guide rnas, methods and uses |
| US11845933B2 (en) * | 2016-02-03 | 2023-12-19 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide RNA and its applications |
| TWI773666B (zh) * | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| AR113154A1 (es) * | 2017-09-29 | 2020-01-29 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para edición del genoma |
-
2019
- 2019-06-07 WO PCT/US2019/036160 patent/WO2019237069A1/en not_active Ceased
- 2019-06-07 SG SG11202011539VA patent/SG11202011539VA/en unknown
- 2019-06-07 BR BR112020024731-6A patent/BR112020024731A2/pt unknown
- 2019-06-07 CN CN201980052704.4A patent/CN112567036A/zh active Pending
- 2019-06-07 IL IL278822A patent/IL278822B1/en unknown
- 2019-06-07 MX MX2020013293A patent/MX2020013293A/es unknown
- 2019-06-07 KR KR1020217000460A patent/KR102919364B1/ko active Active
- 2019-06-07 EP EP19814154.1A patent/EP3802828A4/en active Pending
- 2019-06-07 JP JP2020567951A patent/JP7832761B2/ja active Active
- 2019-06-07 CA CA3102950A patent/CA3102950A1/en active Pending
- 2019-06-07 KR KR1020267002411A patent/KR20260030838A/ko active Pending
- 2019-06-07 IL IL326752A patent/IL326752A/en unknown
- 2019-06-07 AU AU2019282824A patent/AU2019282824C1/en active Active
- 2019-06-10 TW TW108120005A patent/TW202016306A/zh unknown
-
2020
- 2020-12-04 US US17/111,769 patent/US20210087568A1/en active Pending
- 2020-12-07 SA SA520420729A patent/SA520420729B1/ar unknown
- 2020-12-07 PH PH12020552100A patent/PH12020552100A1/en unknown
- 2020-12-07 MX MX2025001112A patent/MX2025001112A/es unknown
-
2021
- 2021-01-06 CO CONC2021/0000051A patent/CO2021000051A2/es unknown
-
2025
- 2025-03-26 JP JP2025052142A patent/JP2025108457A/ja active Pending
-
2026
- 2026-01-21 AU AU2026200415A patent/AU2026200415A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210029772A (ko) | 2021-03-16 |
| KR102919364B1 (ko) | 2026-01-29 |
| AU2019282824C1 (en) | 2026-04-23 |
| JP2025108457A (ja) | 2025-07-23 |
| MX2025001112A (es) | 2025-03-07 |
| KR20260030838A (ko) | 2026-03-06 |
| PH12020552100A1 (en) | 2021-08-02 |
| CO2021000051A2 (es) | 2021-01-18 |
| AU2019282824B2 (en) | 2025-10-23 |
| SG11202011539VA (en) | 2020-12-30 |
| AU2019282824A1 (en) | 2021-01-07 |
| MX2020013293A (es) | 2021-05-12 |
| JP7832761B2 (ja) | 2026-03-18 |
| SA520420729B1 (ar) | 2024-03-17 |
| IL278822A (en) | 2021-01-31 |
| IL278822B1 (en) | 2026-04-01 |
| WO2019237069A1 (en) | 2019-12-12 |
| AU2026200415A1 (en) | 2026-02-19 |
| EP3802828A1 (en) | 2021-04-14 |
| CA3102950A1 (en) | 2019-12-12 |
| US20210087568A1 (en) | 2021-03-25 |
| BR112020024731A2 (pt) | 2021-03-23 |
| CN112567036A (zh) | 2021-03-26 |
| IL326752A (en) | 2026-04-01 |
| EP3802828A4 (en) | 2022-10-26 |
| JP2021526804A (ja) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202016306A (zh) | 用於基因編輯之經修飾引導rna | |
| JP7625555B2 (ja) | 修飾されたガイドｒｎａ | |
| AU2022201266B2 (en) | Targeted rna editing | |
| CN115176001A (zh) | 用于基因编辑的修饰的引导rna | |
| JP2021519071A (ja) | シュードウリジン化のための核酸分子 | |
| TW202334419A (zh) | 用於基因編輯之經修飾引導rna | |
| HK40048090A (en) | Modified guide rnas for gene editing | |
| WO2025180435A1 (en) | Ligation of nucleic acid molecules and the use thereof for genome editing | |
| HK40078499A (en) | Modified guide rnas for gene editing | |
| HK40014268A (en) | Modified guide rnas | |
| HK40014268B (zh) | 经修饰的指导rna |